Search Results - ursula+buchholz

9 Results Sort By:
Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery
This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design...
Published: 12/10/2024   |   Inventor(s): Cyril Le Nouen, Joseph Marcotrigiano, Ursula Buchholz, Peter Collins
Keywords(s):  
Category(s): Application > Research Materials, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...
Published: 12/10/2024   |   Inventor(s): Ursula Buchholz
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2
In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP...
Published: 12/10/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Cindy Luongo
Keywords(s):  
Category(s): Application > Diagnostics, Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Research Equipment, TherapeuticArea > Infectious Disease, TherapeuticArea > Respiratory
Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening
The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers...
Published: 12/10/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Stephanie Biacchesi
Keywords(s):  
Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Research Equipment, TherapeuticArea > Respiratory, TherapeuticArea > Infectious Disease
Mononegavirales Vectors Expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...
Published: 10/28/2024   |   Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir
Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use
Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....
Published: 10/28/2024   |   Inventor(s): Shirin Munir, Cindy Luongo, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Ursula Buchholz
Keywords(s): 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Research Materials
Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene
RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...
Published: 10/28/2024   |   Inventor(s): Cyril Le Nouen, Ursula Buchholz, Peter Collins
Keywords(s): ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease
Mononegavirales Vectors expressing Chimeric Antigens
Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...
Published: 10/28/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir
Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus
Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease
Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation
Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral...
Published: 10/28/2024   |   Inventor(s): Peter Collins, Brian Murphy, Ursula Buchholz, Stephen Whitehead, Christine Krempl
Keywords(s): ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines